BridgeBio Pharma (BBIO) Shares Plunge 1.54% Amid Anticipation of Key Acoramidis Trial Data

BridgeBio Pharma (BBIO) shares fell 1.54% on August 29, 2025, hitting a low not seen since August 2025, with an intraday decline of 3.16%. The selloff came amid anticipation of key data from the ATTRibute-CM trial for Acoramidis, a flagship drug candidate for transthyretin amyloid cardiomyopathy (ATTR-CM). The 42-month results from the open-label extension study, set to be presented at the European Society of Cardiology (ESC) Congress 2025, are critical for validating the drug’s long-term efficacy and addressing lingering concerns about its competitive positioning.

Investor sentiment remains mixed as BridgeBio navigates a pipeline heavily reliant on Acoramidis, despite progress in diversifying its portfolio. Key programs such as AG10, a next-generation TTR stabilizer, and infigratinib for achondroplasia, highlight the company’s focus on rare diseases. However, delays or setbacks in any of these trials could amplify risks given the current concentration in Acoramidis. The recent 2025 Q2 earnings report, while showing a 4999.9% year-over-year revenue increase, also revealed a $0.95 per share loss, underscoring near-term financial pressures.

Analyst optimism contrasts with recent insider selling, which has raised questions about internal confidence. Executives and directors sold shares totaling $2.4 million in August 2025, though the company’s 18.20% insider ownership suggests ongoing alignment with shareholders. Meanwhile, institutional ownership at 99.85% signals strong backing for long-term growth, even as short interest remains elevated. The upcoming ESC 2025 presentation will be pivotal in addressing doubts about Acoramidis’ durability and reinforcing the drug’s differentiation against competitors like Alnylam Pharmaceuticals’ Onpattro.

BridgeBio’s aggressive financial projections—$1.7 billion in revenue and $293.6 million in earnings by 2028—depend on sustained market adoption of Acoramidis and regulatory approvals for its pipeline. However, persistent losses and high R&D costs pose challenges to capital efficiency. With a projected fair value of $62.43 per share, the stock’s trajectory hinges on meeting these ambitious targets while managing risks such as pricing pressures and clinical trial outcomes. The next few months will test the company’s ability to balance innovation with financial sustainability, as investor confidence remains closely tied to the success of its core therapy and strategic execution.